CSLEX (sialyl Lewis X) is a useful tumor marker for monitoring of breast cancer patients

Japanese Journal of Clinical Oncology

Volumn 41, Issue 3, 2011, Pages 394-399

  Fujita, Tomoyuki ^a,b   Murayama, Koichi ^a   Hanamura, Toru ^a   Okada, Toshihiro ^a   Ito, Tokiko ^a   Harada, Michihiko ^a   Komatsu, Akira ^a   Koyama, Hiroshi ^a   Kanai, Toshiharu ^a   Maeno, Kazuma ^a   Mochizuki, Yasuhiro ^a   Hama, Yoshihisa ^a   Ito, Ken Ichi ^a   Amano, Jun ^a   Fujimori, Minoru ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Breast cancer; CSLEX; Metastasis; Tumor marker

Indexed keywords

BCA225 ANTIGEN; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; NATION CANCER CENTER STOMACH 439 ANTIGEN; SIALYL LEWIS X ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN DETECTION; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER DIAGNOSIS; CANCER PATIENT; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; OUTPATIENT DEPARTMENT; PATIENT MONITORING; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SKIN METASTASIS; TREATMENT RESPONSE;

BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; OLIGOSACCHARIDES; PROGNOSIS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 79952393696     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq190     Document Type: Article

References (20)

1. Anonymous. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology. J Clin Oncol 1996;14:2843-77.
2. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 Update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-312.
3. Sell S. Cancer-associated carbohydrates identified by monoclonal antibodies. Hum Pathol 1990;10:1003-19.
4. Berg EL, Magnani J, Warnock RA, Robinson MK, Butcher EC. Comparison of L-selectin and E-selectin ligand specificities: The L-selectin can bind the E-selectin ligands Sialyl Lex and Sialyl Lea. Biochem Biophys Res Commun 1992;184:1048-55.
5. Fukuda M. Possible roles of tumor-associated carbohydrate antigens. Cancer Res 1996;56:2237-44.
6. Kobzdej MM, Leppänen A, Ramachandran V, Cummings RD, McEver RP. Discordant expression of selectin ligands and sialyl Lewis x-related epitopes on murine myeloid cells. Blood 2002;100:4485-94.
7. Phillips ML, Nudelman E, Gaeta FCA, Perez M, Singhal AK, Hakomori S, et al. ELAM-1 mediates cell adhesion by recognition of a carbohydrate ligand, sialyl-Lex. Science 1990;250:1130-32.
8. Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M, et al. Contribution of carbohydrate antigens sialyl Lewis-A and sialyl Lewis-X to adhesion of human cancer cells to vascular endothelium. Cancer Res 1993;53:354-61.
9. Fukushima K, Hirota M, Terasaki PI, Wakisaka A, Togashi H, Chia D, et al. Characterization of sialosylated Lewis x as a new tumorassociated antigen. Cancer Res 1984;44:5279-85.
10. Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T. Cimetidine increases survival of colorectal cancer patients with high levels of sialyl Lewis-X and sialyl Lewis-A epitope expression on tumour cells. Br J Cancer 2002;86:161-7.
11. Renkonen J, Heinävaara S, Sankila R, Paavonen T. Endothelial and epithelial expression of sialyl Lewis(x) in squamous carcinoma of the tongue. APMIS 2000;108:705-12.
12. Kurebayashi J, Nomura T, Hirono M, Okubo S, Udagawa K, Shiiki S, et al. Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients. Jpn J Clin Oncol 2006;36:150-3.
13. Kumamoto K, Mitsuoka C, Izawa M, Kimura N, Otsubo N, Ishida H, et al. Specific detection of sialyl Lewis X determinant carried on the mucin GlcNAcbeta1→6GalNAcalpha core structure as a tumorassociated antigen. Biochem Biophys Res Commun 1998;247:514-7.
14. Satoh H, Ishikawa H, Kamma H, Yamashita YT, Takahashi H, Ohtsuka M, et al. Serum sialyl lewis X-i antigen levels in non-small cell lung cancer: correlation with distant metastasis and survival. Clin Cancer Res 1997;3:495-9.
15. Futamura N, Nakamura S, Tatematsu M, Yamamura Y, Kannagi R, Hirose H. Clinicopathologic significance of sialyl Le(x) expression in advanced gastric carcinoma. Br J Cancer 2000;83:1681-7.
16. Sato T, Nishimura G, Nonomura A, Miwa K, Miyazaki I. Serological studies on CEA, CA 19-9, STn and SLX in colorectal cancer. Hepatogastroenterology 1999;46:914-9.
17. Matsuura N, Narita T, Mitsuoka C, Kimura N, Kannagi R, Imai T, et al. Increased level of circulating adhesion molecules in the sera of breast cancer patients with distant metastases. Jpn J Clin Oncol 1997;27: 135-9.
18. Safi F, Kohler I, Röttinger E, Suhr P, Beger HG. Comparison of CA 15-3 and CEA in diagnosis and monitoring of breast cancer. Int J Biol Markers 1989;4:207-14.
19. Cheung KL, Graves CR, Robertson JF. Tumour marker measurements in the diagnosis and monitoring of breast cancer. Cancer Treat Rev 2000;26:91-102.
20. O'Brien DP, Horgan PG, Gough DB, Skehill R, Grimes H, Given HF. CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients. Ann R Coll Surg Engl 1992;74:9-11.